Do monoclonal antibodies and anticytokines still have a future in infectious diseases?

This publication has 30 references indexed in Scilit:

• A second large controlled clinical study of E5, a monoclonal antibody to endotoxin
  Critical Care Medicine, 1995
• 195 RESULTS OF A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CP-0127, A NOVEL BRADYKININ ANTAGONIST. IN PATIENTS WITH SIRS AND SEPSIS
  Shock, 1995
• 209 CONFIRMING PHASE III CLINICAL TRIAL TO STUDY THE EFFICACY OF A P.A.F. ANTAGONIST, BN 52021 [BN], IN REDUCING MORTALITY OF PTS WITH SEVERE GRAM-NEGATIVE SEPSIS [GNS]
  Shock, 1995
• 203 SAFETY AND EFFICACY OF THE MONOCLONAL ANTI-TNF ANTIBODY-FRAGMENT MAK 195F IN PATIENTS WITH SEPSIS AND SEPTIC SHOCK
  Shock, 1995
• Adjunctive Therapy for Septic Shock: A Review of Experimental Approaches
  Clinical Infectious Diseases, 1995
• Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
  Critical Care Medicine, 1994
• Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future direction
  Innate Immunity, 1994
• Unraveling Function in the TNF Ligand and Receptor Families
  Science, 1994
• Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial
  Critical Care Medicine, 1994
• Mediators of septic shock
  Critical Care Medicine, 1993